Wire · operational-macro
PureTech blood cancer drug wins FDA fast track and clears path to phase 2
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
PureTech Health's experimental blood cancer drug LYT-200 received FDA fast track status, accelerating its development for hard-to-treat myelodysplastic syndromes. Following a successful end-of-phase 1 meeting, the drug is set to enter phase 2 trials with plans for external funding in 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You have a clear path to accelerate your blood cancer drug development in the US thanks to FDA fast track designation. Raising outside capital in early 2027 is your next threshold to keep the progress moving into phase 2.
◆ Coverage
2 sources · 21 Sep 2026
◆ Related on Wire
◆ Topics